Related Experiment Videos
Fluoxetine discontinuation in elderly dysthymic patients
D P Devanand1, M K Kim, M S Nobler
1Late-Life Depression Clinic, New York State Psychiatric Institute, College of Physicians & Surgeons of Columbia University, New York 10032, USA.
Summary
Elderly patients with dysthymic disorder experienced a 50% relapse rate after discontinuing fluoxetine treatment. This relapse rate, while lower than in younger adults, suggests caution is needed when stopping antidepressant medication.
Area of Science:
- Geriatric Psychiatry
- Pharmacology
- Clinical Psychology
Background:
- Dysthymic disorder is a chronic mood disorder affecting elderly individuals.
- Antidepressant efficacy and discontinuation effects in geriatric populations require further investigation.
- Fluoxetine is a selective serotonin reuptake inhibitor (SSRI) commonly used for depression.
Purpose of the Study:
- To evaluate the relapse rate in elderly outpatients with dysthymic disorder after discontinuing fluoxetine.
- To identify predictors of relapse following antidepressant discontinuation in this demographic.
Main Methods:
- A 13-week open-label fluoxetine trial was conducted with 23 elderly outpatients diagnosed with dysthymic disorder.
- Twelve responders continued open treatment and then discontinued fluoxetine.
- Patients were monitored for relapse during the 24 weeks following discontinuation.
Main Results:
- Six out of 12 patients (50%) who discontinued fluoxetine relapsed within 24 weeks.
- No significant predictors of relapse were identified, including clinical features, fluoxetine dosage, or treatment duration.
- The observed relapse rate was lower than previously reported rates in younger adults with dysthymic disorder.
Conclusions:
- Discontinuation of fluoxetine in elderly patients with dysthymic disorder is associated with a substantial relapse rate.
- The findings suggest a need for careful monitoring and management strategies when discontinuing SSRIs in older adults.
- Further research is warranted to understand long-term outcomes and optimize treatment strategies for geriatric dysthymic disorder.